- Home
- DSGN vs MOV Comparison
DSGN vs MOV Comparison
Compare DSGN & MOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- MOV
- Stock Information
- Founded
- DSGN 2017
- MOV 1961
- Country
- DSGN United States
- MOV United States
- Employees
- DSGN N/A
- MOV N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- MOV Consumer Specialties
- Sector
- DSGN Health Care
- MOV Consumer Discretionary
- Exchange
- DSGN Nasdaq
- MOV Nasdaq
- Market Cap
- DSGN 418.1M
- MOV 416.4M
- IPO Year
- DSGN 2021
- MOV 1993
- Fundamental
- Price
- DSGN $8.78
- MOV $19.47
- Analyst Decision
- DSGN Buy
- MOV Strong Buy
- Analyst Count
- DSGN 1
- MOV 1
- Target Price
- DSGN $13.00
- MOV $31.50
- AVG Volume (30 Days)
- DSGN 427.2K
- MOV 108.8K
- Earning Date
- DSGN 11-05-2025
- MOV 11-25-2025
- Dividend Yield
- DSGN N/A
- MOV 7.19%
- EPS Growth
- DSGN N/A
- MOV N/A
- EPS
- DSGN N/A
- MOV 0.77
- Revenue
- DSGN N/A
- MOV $655,597,000.00
- Revenue This Year
- DSGN N/A
- MOV $1.98
- Revenue Next Year
- DSGN N/A
- MOV N/A
- P/E Ratio
- DSGN N/A
- MOV $25.24
- Revenue Growth
- DSGN N/A
- MOV 0.79
- 52 Week Low
- DSGN $2.60
- MOV $12.85
- 52 Week High
- DSGN $8.89
- MOV $22.20
- Technical
- Relative Strength Index (RSI)
- DSGN 68.78
- MOV 61.30
- Support Level
- DSGN $7.25
- MOV $18.23
- Resistance Level
- DSGN $8.80
- MOV $18.82
- Average True Range (ATR)
- DSGN 0.69
- MOV 0.64
- MACD
- DSGN 0.12
- MOV 0.12
- Stochastic Oscillator
- DSGN 93.42
- MOV 96.89
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About MOV Movado Group Inc.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.